Ligand Pharmaceuticals Announces Acquisition Of EMEA Royalty On Santen's Pediatric Myopia Drug Ryjunea From Sydnexis For $23M Upfront
Share
Why It Matters
Ligand bought the right to earn money from a children's eye medicine in Europe. This shows the company is betting on new income sources for the future.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.